Zevra Therapeutics (ZVRA) announced that the Company has executed an exclusive expanded access distribution agreement with Uniphar. The agreement enables Niemann-Pick Disease Type C patients to access MIPLYFFA, for reimbursed named patient supply in select territories outside of Europe.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ZVRA: